Clinical Liver Disease
Issues in selecting HCV-infected candidates for anti-viral treatment, Anna S. Lok - Article Reading
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:07:08
- Mais informações
Informações:
Sinopse
The recent approval of two protease inhibitors (telaprevir and boceprevir) and the resultant increase in the sustained virological response (SVR) rate when either of these drugs is added to pegylated interferon (PEG-IFN) and ribavirin (RBV) have led to a flurry of patients with hepatitis C virus (HCV) infection seeking treatment.
